These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30654041)

  • 1. The safety of atovaquone-proguanil for the prevention and treatment of malaria in pregnancy: A systematic review.
    Andrejko KL; Mayer RC; Kovacs S; Slutsker E; Bartlett E; Tan KR; Gutman JR
    Travel Med Infect Dis; 2019; 27():20-26. PubMed ID: 30654041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of atovaquone-proguanil during pregnancy.
    Mayer RC; Tan KR; Gutman JR
    J Travel Med; 2019 Jun; 26(4):. PubMed ID: 30544231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review and meta-analysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria.
    Nakato H; Vivancos R; Hunter PR
    J Antimicrob Chemother; 2007 Nov; 60(5):929-36. PubMed ID: 17848375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II).
    Boggild AK; Parise ME; Lewis LS; Kain KC
    Am J Trop Med Hyg; 2007 Feb; 76(2):208-23. PubMed ID: 17297027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A survey on outcomes of accidental atovaquone-proguanil exposure in pregnancy.
    Tan KR; Fairley JK; Wang M; Gutman JR
    Malar J; 2018 May; 17(1):198. PubMed ID: 29764439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atovaquone-proguanil for treating uncomplicated Plasmodium falciparum malaria.
    Blanshard A; Hine P
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD004529. PubMed ID: 33459345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic use of antimalarials during pregnancy.
    Irvine MH; Einarson A; Bozzo P
    Can Fam Physician; 2011 Nov; 57(11):1279-81. PubMed ID: 22084457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of atovaquone-proguanil chemoprophylaxis and chloroquine treatment in Plasmodium malariae infection.
    Visser R; de Mast Q; Munnix I; van der Ven A; Dofferhoff T
    Travel Med Infect Dis; 2016; 14(6):644-645. PubMed ID: 27546283
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative benefit of malaria chemoprophylaxis modelled in United Kingdom travellers.
    Toovey S; Nieforth K; Smith P; Schlagenhauf P; Adamcova M; Tatt I; Tomianovic D; Schnetzler G
    Travel Med Infect Dis; 2014; 12(6 Pt B):726-32. PubMed ID: 25443997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugs for preventing malaria in travellers.
    Jacquerioz FA; Croft AM
    Cochrane Database Syst Rev; 2009 Oct; (4):CD006491. PubMed ID: 19821371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atovaquone-proguanil chemoprophylaxis in the era of Tafenoquine.
    Meltzer E; Schwartz E
    J Travel Med; 2019 Jun; 26(4):. PubMed ID: 30535377
    [No Abstract]   [Full Text] [Related]  

  • 12. Atovaquone and proguanil hydrochloride for treatment of malaria.
    Kremsner PG; Looareesuwan S; Chulay JD
    J Travel Med; 1999 May; 6 Suppl 1():S18-20. PubMed ID: 23573548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil.
    Sutherland CJ; Laundy M; Price N; Burke M; Fivelman QL; Pasvol G; Klein JL; Chiodini PL
    Malar J; 2008 Nov; 7():240. PubMed ID: 19021900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atovaquone and proguanil hydrochloride for prophylaxis of malaria.
    Shanks GD; Kremsner PG; Sukwa TY; van der Berg JD; Shapiro TA; Scott TR; Chulay JD;
    J Travel Med; 1999 May; 6 Suppl 1():S21-7. PubMed ID: 23573549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abbreviated atovaquone-proguanil prophylaxis regimens in travellers after leaving malaria-endemic areas: A systematic review.
    Savelkoel J; Binnendijk KH; Spijker R; van Vugt M; Tan K; Hänscheid T; Schlagenhauf P; Grobusch MP
    Travel Med Infect Dis; 2018; 21():3-20. PubMed ID: 29242073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discontinuing atovaquone/proguanil prophylaxis ad-hoc post-exposure and during-travel dose-sparing prophylactic regimens against P. falciparum malaria: An update with pointers for future research.
    Schnyder JL; de Jong HK; Schlagenhauf P; Borrmann S; Hanscheid T; Grobusch MP
    Travel Med Infect Dis; 2022; 49():102365. PubMed ID: 35661741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the potential for discontinuing atovaquone-proguanil (AP) ad-hoc post-exposure and other abbreviated AP-regimens: Pharmacology, pharmacokinetics and perspectives.
    Schnyder JL; de Jong HK; Bache EB; van Hest RM; Schlagenhauf P; Borrmann S; Hanscheid T; Grobusch MP
    Travel Med Infect Dis; 2023; 52():102520. PubMed ID: 36526126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fluindione and falciparum malaria treated by atovaquone-proguanil].
    Kamaliddin C; Joste V; Argy N; Houzé S
    Therapie; 2018 Oct; 73(5):445-447. PubMed ID: 29680373
    [No Abstract]   [Full Text] [Related]  

  • 19. [Atovaquone-proguanil treatment failure in Plasmodium falciparum].
    Contentin L; Grammatico-Guillon L; Desoubeaux G; Baron S; Thanh HD
    Presse Med; 2011 Nov; 40(11):1081-3. PubMed ID: 21570798
    [No Abstract]   [Full Text] [Related]  

  • 20. Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria.
    McKeage K; Scott L
    Drugs; 2003; 63(6):597-623. PubMed ID: 12656656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.